The EPO’s Enlarged Board of Appeal has published its much-awaited decision on G 1/22 and G 2/22 regarding the validity…

The European Patent Office’s (EPO) Enlarged Board of Appeal’s decision in G2/21 primarily relates to when data that only becomes…

As many will already be aware, M&S and Aldi recently called a truce in the viral dispute involving the M&S…

Background The UK IPO’s approach in handling communications arising out of third-party actions filed against UK trade mark and design…

The current go-live date for the Unitary Patent (UP) and the Unified Patent Court (UPC) is 1 June 2023. For…

What may have originally seemed to be the realms of science fiction is slowly becoming reality. This creates many problems,…

Clinical trials are an expensive and risky business. The investment of time, resources and costs grows with progression through the…

Intellectual Property (IP) law is not something that easily attracts the UK public’s attention. However this changed significantly when the…

A peculiarity of patent prosecution at the EPO is that examiners typically insist on the description being amended into line…

In some fields – such as chemistry, biology and physics – results are not totally predictable. However, it can be…

The pharmaceutical industry has eagerly awaited the decision from the US Food and Drug Administration (FDA) on the first new…

Background Peloton, one of the world’s leading indoor exercise bike manufacturers, has found itself in what appears to be a…